Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients.
about
Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAsmiR-29a-deficiency does not modify the course of murine pancreatic acinar carcinoma.Prognostic impact of MYH9 expression on patients with acute myeloid leukemia.MicroRNA: an important regulator in acute myeloid leukemia.Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders.Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia.
P2860
Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical response to azacitidi ...... eloid leukemia (AML) patients.
@en
Clinical response to azacitidine therapy depends on microRNA-29c
@nl
type
label
Clinical response to azacitidi ...... eloid leukemia (AML) patients.
@en
Clinical response to azacitidine therapy depends on microRNA-29c
@nl
prefLabel
Clinical response to azacitidi ...... eloid leukemia (AML) patients.
@en
Clinical response to azacitidine therapy depends on microRNA-29c
@nl
P2093
P2860
P356
P1433
P1476
Clinical response to azacitidi ...... yeloid leukemia (AML) patients
@en
P2093
Aleksandra Butrym
Dagmara Baczyńska
Justyna Rybka
Kazimierz Kuliczkowski
P2860
P304
30250-30257
P356
10.18632/ONCOTARGET.7172
P407
P577
2016-05-01T00:00:00Z